EGM
TARA icon

Engineers Gate Manager’s Protara Therapeutics TARA Stock Holding History

Engineers Gate Manager’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-21,200
Closed -$110K – 2606
2026
Q1 		$110K Sell
21,200
-686
-3% -$4.06K ﹤0.01% 2007
2025
Q4 		$117K Buy
+21,886
New +$122K ﹤0.01% 1897

Other funds holding TARA

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.53B AUM 154.61% 1-Year Est. Return

Engineers Gate Manager's TARA Position: Q2 2026 in Review

Engineers Gate Manager sold out of Protara Therapeutics (TARA) in Q2 2026, closing a stake of 21,200 shares — an estimated $110K sold.

Engineers Gate Manager first reported a position in TARA in Q4 2025 and held it in 2 quarters. The position peaked at $117K in Q4 2025. 120 funds tracked by Wall St. Rank hold TARA as of Q2 2026.

  • Engineers Gate Manager reported no remaining Protara Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Engineers Gate Manager sold 21,200 Protara Therapeutics shares in Q2 2026, an estimated $110K.
  • Engineers Gate Manager first reported a position in Protara Therapeutics in Q4 2025 and held it in 2 quarters.
  • Engineers Gate Manager's Protara Therapeutics position peaked at $117K in Q4 2025.
  • 120 funds tracked by Wall St. Rank held Protara Therapeutics as of Q2 2026.

Based on Engineers Gate Manager's 13F filing for Q2 2026, filed 14 Aug 2026.